ABSTRACT
It has long been understood that administering chemotherapy at a metronomic pace has a greater, more distinct biological impact than doing so at a maximally tolerated dose (MTD). Preclinical studies have clearly illustrated these distinctions, and several clinical trials have shown reproducible action, albeit modest, in a variety of solid tumors even in individuals who had received an extensive amount of pretreatment. The effectiveness and tolerance of many monotherapies and combinations of chemotherapeutic drugs when given at metronomic dosages have been demonstrated in several clinical trials. Recent research trends indicate that metronomic therapy is an effective therapeutic choice for certain patients with metastatic breast cancer (MBC). A potential novel strategy for treating MBC may also be represented by its inclusion in immunological and targeted treatments given its multimodal methods of action. This chapter is intended to provide insight into the utilization of metronomic chemotherapy in cancer, the imaging methods available, and the feasibility of biomarkers.
